BresMed at Virtual ISPOR 2021
This year’s theme for ISPOR is “HEOR: Evolving for Tomorrow’s Challenges” While the conference is taking place virtually this year, we’re happy to still be contributing a range of workshops, panels and posters.
US ISPOR normally provides us with the chance to catch up with the people we work with throughout the year, and though this year looks different we’re also still available to chat. You can contact us if you’d like to arrange a meeting or if you are attending the virtual event you can chat with us during the event by visiting our company page.
|Date & time||Code||Title||Moderator||Panelists|
Wednesday 19 May 13:45-14:45
(Breakout Session 3)
Real World Evidence Utilization Challenges: Building an Integrated System of RWE Data Transparency, Stakeholder Outreach and HTA Acceptance
Laura E. Happe, Jonathan Kowalski, Robert J. Matheis.
|Date & time||Code||Title||Discussion leaders|
|Thursday 20 May 10:00-11:00
(Breakout session 4)
|W11||Science, art or arbitrariness? Evaluating the risk of treatment waning for novel oncology therapies||Raquel Aguiar-Ibáñez, Gianluca Gianluca Baio, Nick Latimer, Dawn Lee.|
|PCN: Cancer||PCN31||Matching Adjusted Indirect Treatment Comparison of FGFR2+ Patients in the Fight-202 Trial VS. Patients with Unspecified FGFR2 Status Receiving Standard of Care Treatments||Galeone C, Gregory J, Patterson K, Reason T, Macarulla T, Sabatelli L.|
|PCN: Cancer||PCN44||Cost-Effectiveness of Durvalumab Following Chemoradiotherapy in Unresectable STAGE III NSCLC Patients in the US: An Update Based on 4-Year Survival DATA||Seal B, Mooradian MJ, Van Keep M, Dunlop W, Brannman L, Yong C.|
|PSS: Sensory System Disorders||PSS5||The Cost-Effectiveness of Dexamethasone Intravitreal Implant Versus Anti-Vascular Endothelial Growth Factor Therapies for Eyes with a Phakic Lens in UK Clinical Practice||Lebbink E, Morgan P, Tefos F, Lowry C.|
|PRO: Rare & Orphan Diseases||PRO15||Healthcare Resource Utilization Associated with NON-Dystrophic Myotonia: Results from a Delphi Panel||Omar A, Chapman AM, Schurer M, Lee H, Ellis C.|
|PIN: Infectious Diseases||PIN28||A US Payer Cost-Effectiveness Analysis of Imipenem/Cilastatin/Relebactam Versus Colistin PLUS Imipenem/Cilastatin in Patients with Carbapenem-Resistant Bacterial Infections||Naik J, Ralph L, Massello M, Dillon R, Mccann E, Yang J.|
|PIN: Infectious Diseases||PIN67||Real-Time Analysis of COVID-19 DATA Using Sequential Monte Carlo Methods||Sheinson D, Meng Y, Elsea D.|